<?xml version="1.0" encoding="UTF-8"?>
<p id="Par55">Lopinavir–ritonavir is a fixed-dose drug combination used for the prevention and treatment of HIV infection and works by inhibiting protease activity
 <sup>
  <xref ref-type="bibr" rid="CR159">159</xref>
 </sup>. Lopinavir is available only in combination with ritonavir, which functions to slow the breakdown of lopinavir by inhibiting cytochrome P450 3A4 (ref.
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup>). In a randomized, controlled, open-label trial involving 199 patients with COVID-19, no benefit was observed with lopinavir–ritonavir treatment compared with standard care
 <sup>
  <xref ref-type="bibr" rid="CR159">159</xref>
 </sup>. Gastrointestinal adverse effects were more frequently reported in the lopinavir–ritonavir treatment group than in the standard group, but adverse cardiovascular effects were not reported in either group
 <sup>
  <xref ref-type="bibr" rid="CR159">159</xref>
 </sup>. Nevertheless, lopinavir–ritonavir should be used with caution in patients with COVID-19 because this drug combination might interact with common cardiovascular drugs that are metabolized by cytochrome P450 3A4, including antiarrhythmic agents, antiplatelet drugs and anticoagulants
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>,
  <xref ref-type="bibr" rid="CR160">160</xref>
 </sup>.
</p>
